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NamibiaIntroduction: All antiretroviral therapies (ARTs) are potentially toxic to the liver. In sub-Saharan Africa,
the rising incidence of ART induced adverse events has complicated treatment leading to recent revisions
of Namibian ART guidelines. Unfortunately there have been limited studies to date evaluating ART
induced liver injury in Namibia to guide further revisions if needed.
Objective: Determine the current patterns and grades of ALT elevation in Namibia’s HIV/AIDS.
Methods: Retrospective cohort analysis. Patterns of alanine amino transferase (ALT) liver enzyme eleva-
tion were determined in a cohort of ART naïve HIV patients on firstline ART regimen in a referral hospital
in Namibia over a 1 year treatment period. Patterns of ALT changes at baseline, 3 months and 6 months
were analyzed using ANOVA and Bonferroni test for pairwise comparisons.
Results: Of 79 eligible patients, 72 developed significant ALT elevation within 3 months of ART initiation
(F (3, 76) = 6.4, p = 0.002, g2 = 0.193). Four 4 (5.6%) and 1 (1.38%) patient respectively developed grade 2
and grade 3 ALT elevation by month 3. There was no significant difference between mean ALT levels at
baseline and month 6. A CD4 count of <350 cells/mm3; female gender and age over 40 years were the
main factors associated with moderate or severe ALT elevation.
Conclusions: First line ART commonly induces mild self-limiting liver enzyme elevation in Namibian HIV
patients especially in the first 3 months. Consequently, there is a need to monitor ALT levels for at least
3 months after initiation mainly in high risk patients to reduce side-effect concerns. This is already
happening.
 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Namibia living with the infection.2,3 Since the rollout of antiretrovi-HIV/AIDS has devastated public health in sub-Saharan Africa.
This is a concern since this region despite being resource con-
strained hosts over 80% of the world’s HIV patients.1 Within Africa,
UNAIDS ranks Namibia among countries with the highest preva-
lence of HIV/AIDS among adults aged 15–49 years (14.3%), with
currently over 250,000 people out of a population of 2.3 million inral therapy (ART) in Namibia in 2003, over 104, 531 (80%) HIV/AIDS
patients have been initiated on treatment.3,4 Recently the test and
treat policy has led to a considerable scale up of patients on first-
line ART regimens. Unfortunately scale-up of ART exposes some
patients to adverse drug reactions (ADRs)5–10 with liver damage
characterized by an elevation of alanine aminotransferase (ALT)
being the most common.11–14 Pharmacovigilance reports in
Namibia have shown an increasing incidence in adverse effects that
parallel the scale-up of ART,15 particularlywith stratification by CD4
count,15–20 female sex12,20 and the use of non-nucleoside reverse
transcriptase inhibitors (NNRTIs).19-25
The high number of female patients initiating ART15,26 is an
important risk factor for ART induced adverse effects including
renal impairment - with hormonal differences playing a part.15,21
Despite these risk factors, ART initiation policies in Namibia has
2 P.A. Mataranyika et al. / Alexandria Journal of Medicine xxx (2017) xxx–xxxevolved based on increasing CD4 thresholds: 250 cells/mm3
(2003); 350 cells/mm3 (2010); 500 cells/mm3 (2014) and currently
to test and treat.27–29 Unfortunately to date, there have been only a
limited number of studies evaluating the grades and risk factors for
ART induced hepatotoxicity among the Namibian HIV/AIDS popu-
lation. This is particularly important as the risk for ART induced
hepatotoxicity among HIV patients in Namibia may be heightened
by the high rates of tuberculosis (TB),30 high alcohol consumption
per capita (12.28 L per person per year)31 and the use of efavirenz
and/or nevirapine based therapies as first line ART treatment in
line with recommendations.20,22–25,27–29 TB coinfection and co-
medication is an important risk factor for hepatotoxicity.32,33 Liver
damage characterized by elevation in liver transaminases through
alanine amino transferase (ALT) is the most reliable marker for
hepatocellular toxicity11,20,34–36; however, it’s measurement
among patients on firstline ART in Namibia is currently unknown.
The routine monitoring of ALT in Namibia is complicated by lim-
ited human resource capacity, which may negatively impact on
treatment outcomes in some patients.
Consequently, the aim of this paper was to determine the cur-
rent patterns and grades of ALT elevation in Namibia’s HIV/AIDS
population to provide future guidance to the authorities in Nami-
bia and other African countries with similar profiles of patients
with HIV. This is because ADRs negatively impact on treatment
adherence,16 health related costs, and the social-psychological
wellbeing of patients37 as well as patient outcomes including their
quality of life.8,38–42 Increased morbidity and mortality related to
ADRs is the main reason for revision and switching ART treatment
as seen in the HIV guidelines in the Namibia.8,9,27–29,43 The use of
AZT based regimens from 2003 to 20,010 was associated with ane-
mia, and stavudine (d4T) based regimens from 2010 to 2015 was
associated with peripheral neuropathy.27–29 The currently pre-
ferred Tenofovir-based regimens15 have been associated with renal
insufficiency and bone dimineralization.15,20,43 Despite these risk
factors for liver damage among the Namibian population, evidence
on patterns and prevalence of liver toxicity remains limited.2. Methods
2.1. Study subjects
The study adopted a retrospective cohort analysis of grades and
risk factors for ALT elevation among patients on firstline ART reg-
imens. The study population consisted of clinical and laboratory
records of patients initiated on first-line ART at Katutura Interme-
diate Hospital (KIH). This is a teaching referral hospital in Wind-
hoek; the capital city of Namibia, and cares for over 5800
patients on active ART from across the Khomas region and
Namibia.
Retrospective data was collected over a 12 month period
between 1st January 2013 and 1st January 2014. The study
included records of all adult HIV/AIDS patients (18 years) who
completed at least 12 months of treatment of first line ART
regimen.
The first line regimens in this study included tenofovir/lamivu
dine/nevirapine (TDF/3TC/NVP) or tenofovir/lamivudine/efavirenz
(TDF/3TC/EFV) combinations. For consistency and reliability, only
records on ALT levels that had been provided by the National Insti-
tute of Pathology (NIP) laboratory at KIH were included. All the
serum levels of ALT of records included in this study were deter-
mined by Architect ci8200 Dxc analyzer (Abbot Diagnostics) as
per the International Federation Clinical Chemistry protocol (IFCC).
Patients with severe ALT elevation at baseline and/or with missing
laboratory records on ALT levels at 3 months and or 6 months were
excluded from the study.Please cite this article in press as: Mataranyika P.A., et al.. Alex J Med (2017),Out of the 123 patients who had the first line ART at KIH
between January 2013 and 31 January 2014, 44 patients were
excluded as their records did not have ALT measurements at
month 3 or month 6. Consequently, a total of 79 patient records
that met the eligibility criteria were included in the study.
2.2. Procedure
Laboratory data on the liver enzyme (AST) and (AST) profiles of
ART naïve patients were collected using quantitative methods over
a 12 month period and five time points - baseline and months 3, 6,
9 and 12 of treatment. Data from the patients’ records were
abstracted by the principal researcher (PAM) from patient ART
treatment records over a 3 months study period - May 2014 to
August 2014 using a pre-tested abstraction tool (Appendix A). Data
abstracted includes demographic, clinical and laboratory data at
baseline, 3 and 6 months. Data collection tools were designed to
exclude patient identifiable data including patient names.
The main outcome variable was the grades and risk factors for
ALT elevation at 3 months and 6 months of ART treatment. Data
was double entered into Epidata (version 3.1) entry software for
management and exported to SPSS (version 21) software for
quantitative analysis. The grades of ALT elevation were determined
using descriptive statistics such as frequencies (%), mean(X) and
standard deviation (SD). The risk factors and patterns of ALT eleva-
tion were determined using a chi-square test (v2) for categorical
variables and student t-test and/or ANOVA test for continuous vari-
ables. The Bonferroni pair-wise Post-hock test was used to com-
pare the mean ALT levels at baseline with months 3 and month 6
post ART initiation. The significance level for a 95% confidence
interval was set at a p value < 0.05. Missing data were excluded
in the analysis.
2.3. Criteria for grading ALT elevation
The grades of ALT elevations were determined using the WHO
toxicity scale based on the upper limits of normal (ULN) ALT
levels,35 that is normal or grade 1 (<2.5  ULN); mild - moderate
elevation or grade 2 (2.5–5  ULN); severe elevation or grade 3
(>5  ULN) or grade 4 (>10  ULN). The normal limits of ALT levels
were considered to be 0–40 IU/L.34,44,45
2.4. Ethics
The study was approved by the University of Namibia (UNAM),
the Ministry of Health and Social Services (MoHSS) and Namibia
Institute of Pathology (NIP) research and ethics committees. The
need for informed consent was waved by the research committee
as the study was based on patient records with no direct contact
with patients. Patient codes or serial numbers were used instead
of patient identifiers such as names to delink the patients from
the data collected. All collected data was safely stored.
3. Results
A total of 79 patient records that met the eligibility criteria were
included in the study. 44 patients were excluded as their records
did not have ALT measurements at month 3 or month 6.
3.1. Baseline demographic and clinical characteristics
The majority of the study subjects were female (n = 51 (65%),
p = 0.01) aged between 30 and 40 years (n = 41 (52%), p = 0.000);
were not married (76%), (p = 0.000) and did not consume alcohol
(n = 61(78%); p = 0.149). The majority of the subjects were initiatedhttp://dx.doi.org/10.1016/j.ajme.2017.03.002
Table 1
Baseline demographic and clinical characteristics of the study subjects (n = 79).
Characteristic Total (%) v2 P-valuea
Sex
Female 51(65)
Male 28(35) 6.696 0.010
Age category
20–30 years 11(14)
31–40 years 41(52)
41–50 years 20(25)
>50 years 7(9) 36.359 0.000
ART regimen
TDF/3TC/EFV 14(18)
TDF/3TC/NVP 65(82) 21.525 0.000
Alcohol consumption
Yes 17(22)
No 62(78) 2.082 0.149
Clinical stage
Stage 1 45(63)
Stage 2 14(22)
Stage 3 18(11)
Stage 4 3(4) 30.490 0.000
CD4 categories
<250 cells/mm3 40(52)
251–350 cells/mm3 29(38)
351–500 cells/mm3 5(6.5)
>500 cells/mm3 3(3.5) 25.224 0.000
Co-infection 1st visit
TB 7(2)
No signs 72(98) 24.352 0.000
Adherence to ART
>90% 64(92)
70–87% 6(5)
<90% 5(3) 11.109 0.004
Medicines on 1st visit
Co-trimoxazole therapy 72(98)
TB treatment & CTX 7(2) 24.352 0.000
a Pearson chi-square test.
Table 2
Patterns of biomarkers for HAART efficacy and toxicity among the subjects.
Characteristic Mean ± SD v2
ALT (IU/L)
Baseline 29.85 ± 23.977
Month 3 50.62 ± 41.035
Month 6 44.12 ± 35.461 2.810
CD4 (cells/mm3)
Baseline 265.00 ± 141.033
Month 2 433.82 ± 181.226 0.000
Haemoglobin (g/dL)
Baseline 12.026 ± 2.2339
Month 6 13.617 ± 1.8127
Month 9 13.561 ± 1.7188 2.970
Serum creatinine (mmol/L)
Baseline 73.82 ± 13.553
Month 3 69.27 ± 13.854
Month 6 71.05 ± 18.269
Month 9 73.09 ± 15.826 26.869
Body weight (kg)
Baseline 63.552 ± 13.5028
Month 1 63.772 ± 13.5840
Month 2 64.400 ± 13.9013
Month 3 65.534 ± 13.7929
Month 4 66.085 ± 13.3924
Month 5 65.628 ± 13.7351 109.262
NB: ALT: Alanine amino transferase.
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ical state 1 or 2 (n = 59 (85%), p = 0.000) with a CD4 count of
<350 cells/mm3 (n = 69 (89.6%), p = 0.000); did not have TB co-
infection (n = 72 (98%), p = 0.000) and had an ART adherence level
of >90% (n = 64(92%), p = 0.000) (Table 1).
3.2. Patterns of alanine amino transaminase (ALT) elevation among
study subjects
The analysis of variance (ANOVA) of the mean ALT levels among
study subjects at baseline, month 3 and month 6 after the initiation
of first line, ART was statistically significant (F (3, 76) = 6.4,
p = 0.002, g2 = 0.193) (Table 2).
This suggests evidence to conclude there is a difference
between the ALT levels by initiation and duration of ART treatment
with an appreciable effect size (g2 > 0.14). A post hoc comparison
to evaluate pair wise difference between the mean ALT levels at
baseline, month 3 and month 6, using the Bonferroni test to control
for type I error, showed a significant increase in the mean ALT
levels between baseline and month three (p = 0.001) as well as
baseline and month six after the initiation of ART (p = 0.02). The
ALT levels were higher at month three and month 6 compared to
baseline (Table 3).
3.3. Prevalence of grades of ALT elevation among the study subjects
Out of the 79 patients at baseline, 77 (97.5%) and 2 (2.5%) had
grade 1 and grade 2 ALT elevation respectively. At 3 months post
ART initiation, out of the 72 (91.1%) patients who had their ALT
results recorded; 67 (93.1%) had grade 1, 4 (5.6%) had grade 2
and 1 (1.34%) had grade 3 ALT elevation. At 6 months post ART ini-
tiation, out of the 66 (83.5%) patients who had their ALT deter-
mined; 62 (93.9%) had grade 1 and 4 (6.1%) had grade 2 ALT
elevation. Out of the five 5 (6.9%) patients that developed grade 2
or 3 ALT elevation by month 3 post ART initiation, the majority
were taking a NVP based regimen, had a baseline CD4 count
<350 cells/mm3, were of the female gender, were aged more thanF g2 P-value
6.940 0.193 0.002
42.761 0.466 0.000
9.975 0.487 0.001
2.969 0.319 0.580
3.330 0.217 0.010
http://dx.doi.org/10.1016/j.ajme.2017.03.002
Table 3
Pair wise comparison of ALT levels at base line, month 3 and month 6.
Characteristic Mean difference Pa-value
ALT month 0
ALT month 3 20.767 0.001
ALT month 6 14.267 0.020
ALT month 3
ALT month 0 20.767 0.001
ALT month 6 6.500 0.500
a Bonferroni post hoc test.
Table 4
Factors associated with elevation of ALT at month 3 (n = 5).
Characteristic # of patients by ALT
elevation
Total (%) P-value
Grade 2 Grade 3
CD4 counts
<250 cells/mm3 2 – 2(40)
251–350 cells/mm3 2 1 3(60) 0.361
ART regimen
TDF/3TC/EFV 1 1 (20)
TDF/3TC/NVP 3 1 4(80) 0.576
Sex
Male 1 1 (20)
Female 3 1 4(80) 0.576
Age of patient
41–50 years 3 3(75)
>50 years 1 1(25) 0.046
Clinical stage
Stage 1 3 1 4(80)
Stage 3 1 – 1(20) 0.576
Alcohol intake
Yes 1 1 (20)
No 3 1 4(80) 0.576
TB coinfection
Yes 1 1 (20)
No 3 1 4(80) 0.576
Fig. 1. Grades of ALT elevations by sex of p
Fig. 2. Grades of ALT elevations by sex of patient after 3 months of ART initiation.
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The study also found that the initiation of ART significantly
increased mean CD4 counts, level of haemoglobin and the patient’s
body weight. The first ART regimen was associated with an
increase in the mean serum creatinine levels also increased after
the initiation of ART (Table 4; Fig. 3).
There were a higher number of female patients with normal –
grade 1 and 2 - as well as with severe liver enzyme elevation
(Fig. 1). The elevation in ALT at 3 months was associated with
the baseline ALT levels (Fig. 2) and CD4 count. The elevation in
ALT was negatively correlated with the baseline CD4 counts
(Fig. 3).
4. Discussion
We found that first line ART regimens were associated with sig-
nificant elevation of ALT from baseline to 3 months, with ALT levelsatient after 3 months of ART initiation.
http://dx.doi.org/10.1016/j.ajme.2017.03.002
Fig. 3. Grades of ALT elevations by CD4 counts after 3 months of ART initiation.
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studies by Lucien et al., Uberti-Foppa, Teklay et al. and De Maat
et al. who found an increased ALT elevation following ART with
in the first month of treatment.7,11,22,35 Studies have associated
NNRTI based regimens with early onset of ALT elevations.16,39,45
However our findings differ from studies by Lucien et al., Splenger
et al., and Bossi et al., regarding the patterns of the ALT elevation,
which showed long term elevation of ALT with duration of treat-
ment.6,11,17 These studies, unlike our study, evaluated regimens
with thymidine analogues (AZT or d4T) that have been associated
with long term mitochondrial toxicity related liver damage.39 This
is unlike this study where adenosine analogue (TDF) based regi-
mens were used, and have been referred to as safe to the liver.8
TDF regimens were used as currently the recommended first line
ART regimen in Namibia is TDF/lamivudine (3TC)/Nevirapine
(NVP) or Efavirenz (EFV).29
We also found a low incidence of moderate or grade 2 ALT ele-
vation in 4 patients (5.6%) and severe or grade 3 elevation in only 1
patient (1.39%) who had ALT elevation at 3 months of ART initia-
tion. Studies in Ethiopia, Zambia, and Palmon et al. also showed
mild liver enzyme elevation in patients initiated on TDF based reg-
imens.7,9,23 However these findings differ from those of Martinez
et al., Sulkowsky, Verucchi et al., Tetrault et al. and Manfredi
et al., whose incidence of severe ALT elevation were 8% and
17.5% for EFV and NVP respectively.18,24,25,46,47 A study in Camer-
oon by Lucien et al. found 22.67% (34/150) presented with
transaminitis with respect to ALT,11, with a study undertaken in
the US among 352 subjects found 81 subjects developed elevated
liver enzymes over the 96 week follow up period.19 In this US
study, the cumulative incidence of liver enzyme elevation was
5.7% at month 1, 9.2% at month 2, 11.5% at month 3, 17.3% at
month 6 and 19% at month 9.19 A slightly higher rate of efavirenz
associated hepatotoxicity (12.5%) was observed in a prospective
cohort study by Maggiolo et al. and Shubber et al.12,14 Whilst not
statistically significant, our study found that grade 2 (moderate)
and or grade 3 (severe) ALT enzyme elevations were associated
with the use of NVP based regimens, initiation of ART in patients
in the WHO Clinical Stage I, and older than 40 years. This was sim-
ilar to the findings of Lucien et al., Spengler et al., and Hawkins
et al., where ALT elevations were greater in patients >40 years,
females and having a CD4 count of less than 350 cells.6,11,48 Previ-
ous studies have associated liver damage with the NVP based reg-Please cite this article in press as: Mataranyika P.A., et al.. Alex J Med (2017),imens20,22–25 and the female sex.16 The higher incidence may
parallel the higher enrollment of female patients on ART pro-
grammes in African countries.15,26–29 Contrary to findings of this
study (Fig. 2), liver toxicity of NVP base ART regimens has been
associated with higher CD4 counts of >250 in female patients
and >400 cell m3 in male patients.45 This may be because these
studies have traditionally been undertaken among Western coun-
tries with different patient populations and pharmacogenomics.26
We accept that the main limitation of this study is the retro-
spective design – with a number of patients missing complete
records on their ALT measurements; consequently, they were
excluded. A prospective randomized clinical trial is ideal but may
not be realistic in settings with limited resources. This is consistent
with the fact that most studies in the African setting on ART
induced liver damage have used retrospective data.5,11 However,
we controlled for bias with paired samples in our study design.
In addition, we were also aware that this study was undertaken
in only one center in Namibia. Never-the-less we believe in view
of the fact that we had 79 patients with paired ALT measurements
(3  79 tests) for 3 months, and ANOVA analysis indicated signifi-
cant differences at different treatment time points, that our find-
ings are robust and would not have been different if we had
included additional patients or additional centers in Namibia.5. Conclusion
First line ART regimens commonly induce mild self-limiting
liver enzyme elevation in Namibian HIV patients especially in the
first 3 months of therapy. However, the incidence of moderate to
severe first line ART induced liver toxicity is low. Patients of the
female gender, aged over 40 years with a CD4 count of <350 and
the use of NVP based regimens may be at greater risk of developing
moderate to severe liver damage. Consequently, there is a need to
monitor ALT levels for at least the first three months after initiation
of therapy mainly in female patients, patients with grade >2 ALT
elevations at baseline and patients with low CD4 counts, as well
as patients on co-medication for tuberculosis.
In view of this, a different approach to monitoring liver toxicity
may be warranted and should be incorporated in guidelines to
monitor ART toxicity. This approach should be based on clinical
signs and symptoms for hepatocellular injury such as jaundice as
well as asymptomatic elevations in ALT at baseline and three
months for all patients initiated on ART. We believe based on our
findings that patients with high risk of hepatocellular damage such
as low baseline CD4 count, of female sex, and >grade 2 ALT eleva-
tions, and patients who test positive for HBV/HCV, should be mon-
itored for at least 6 months after initiation of NVP and EFV based
antiretroviral therapy. The Ministry of Health in Namibia has
started to implement these practices, and we will be monitoring
the results in future research projects. These findings may also
be of interest to other African countries.Conflict of interest and funding
The authors hereby declare that they have no conflicts of inter-
est to disclose. There was no external funding for this project.Acknowledgements
The authors would like to acknowledge the contribution from
the National Institute of Pathology of Namibia for the permission
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A.1. Data entry tool
First-line antiretroviral therapy induced liver enzyme elevation
in a cohort of HIV/AIDS patients in Namibia: findings and
implications
100. Serial number 
Patient information
101. Patient ID 
102. Gender                       (1)        male (2)        female 
103. Date of birth 
104. Confirmed HIV status      (1)        yes       (2)        no 
105. Date ART started
106. Regime        (1)        TDF/3TC/EFV            (2)        TDF/3T
other ________________ 
107. Weight (kg) 
108. Clinical stage (1)        I    (2)        II          (3)        III
(5)        not stated 
109. CD4 count (cells/uL)
110. Marital status (1)        single  (2) married (3)       
other_________________ 
111. Alcohol intake (1)         yes (2)         no 
ART card
112. 
Date  
113.Weight 
(kg) 
114.Clinical 
stage of HIV 
115.Co-
infections 
116.New 
problems (co-
morbidities) 
117
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Parameter  Base
line 
Mo
nth 
1 
Mo
nth 
2 
Mo
nth 
3 
Mo
nth 
4 
Mo
nth 
5 
Mo
nth 
6 
Mo
nth 
7 
119. 
Haemoglobin(g
/dl) 
120.Creatinine 
clearance(umol
/L) 
121. ALT(u/L) 
122. Viral load 
123. CD4 
count 
(cells/uL) 
124. 
Hematocrit (%) 
125. 
Neutrophils(x1
09/L) 
126.Lymphocy
tes(x109/L) 
127. Total 
WBC(x109/L) 
128.Platelets 
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